Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2018
Filing Date: March 6, 2018
This filing serves as a cover document for an Investor Roadshow Presentation (Exhibit 99.1) conducted in March 2018. The registrant is an Irish-domiciled company with principal executive offices in Dublin.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a procedural filing to submit an external presentation rather than a financial statement containing tabular data.
Material Changes
No material changes to financial results or operations are detailed within the text of this specific filing. The document references the "consummation of the Fermacell acquisition and integration" as a forward-looking factor but does not provide specific update metrics in this text.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains extensive disclosures regarding forward-looking statements, including projections on future performance, capital expenditure projects, credit facility renewals, dividend payments, and share buy-backs.
Key Risks and Contingencies:
- Asbestos Liability: Significant exposure related to prior manufacture of asbestos-containing products, including contributions to the Asbestos Injuries Compensation Fund (AICF) and potential shortfalls.
- Legal Proceedings: Risks associated with product liability, environmental matters, and consumer class actions.
- Market Conditions: Dependence on US and Asia Pacific housing markets, new home construction levels, and consumer confidence.
- Operational Risks: Integration of the Fermacell acquisition, raw material costs, and currency exchange rate fluctuations.
- Regulatory and Tax: Changes in tax laws, environmental regulations, and health and safety laws.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Investor Roadshow Presentation) for specific financial guidance and operational metrics not included in this cover letter.
- Verify the current status and funding adequacy of the Asbestos Injuries Compensation Fund (AICF).
- Monitor the integration progress and financial impact of the Fermacell acquisition.
- Assess exposure to currency exchange rates given the company's international operations (US, Australia, Ireland).
- Check for updates on pending legal proceedings and warranty provision estimates.